Case Report: A Rare Case of Pembrolizumab-Induced Bullous Pemphigoid

被引:6
|
作者
Zhang, Xiaoyan [1 ]
Sui, Dongjiang [1 ]
Wang, Dong [1 ]
Zhang, Lina [1 ]
Wang, Ruiyan [2 ]
机构
[1] Air Force Med Ctr, Dept Pulm & Crit Care Med, Beijing, Peoples R China
[2] Air Force Med Ctr, Dept Dermatol, Beijing, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
关键词
bullous pemphigoid; pembrolizumab; programmed cell death protein 1; immunotherapy; glucocorticoid; ADVERSE EVENTS; INHIBITORS; MANAGEMENT; CANCER; PD-1;
D O I
10.3389/fimmu.2021.731774
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The programmed cell death protein 1 inhibitor pembrolizumab, an immune checkpoint inhibitor, has subsequently been approved for the treatment of a wide variety of malignant tumors. Compared with conventional chemotherapy, immunotherapy is associated with a unique set of immune reactions, known collectively as immune-related adverse events. Although often mild, dermatologic toxicity can occasionally be high grade and potentially life-threatening. Here we describe a rare case of bullous pemphigoid (BP) associated with pembrolizumab. A 79-year-old male patient presented with scattered erythema, papules, blisters, and pruritus after pembrolizumab treatment. Then, the rash gradually aggravated and spread to the whole body. The extensive edematous erythema, blisters, bullae, and blood blisters were loose and easy to rupture, forming an erosive surface and with pruritus and obvious pain. The hemidesmosomal protein BP180 (type XVII collagen) was detectable in the serum, and the histological examination diagnosis was bullous pemphigoid. After 10 days of glucocorticoid (methylprednisolone, iv, 80 mg/day) treatment, new blister formation ceased. We need to increase the awareness on and facilitate the earlier identification of the cutaneous adverse effects of BP with immunotherapy so that treat can begin early in order to limit the duration and severity of toxicity.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report
    Pop, Samantha R.
    Strock, Daniel
    Smith, Robert J.
    DERMATOLOGIC THERAPY, 2022, 35 (08)
  • [2] Pembrolizumab-induced bullous pemphigoid
    Kartha, Virginia
    Owen, Cindy
    Callen, Jeffrey P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB218 - AB218
  • [3] Intravenous immunoglobulin for pembrolizumab-induced bullous pemphigoid-like eruption: A case report
    Hoshina, Daichi
    Hotta, Moeko
    DERMATOLOGIC THERAPY, 2022, 35 (12)
  • [4] Pembrolizumab-induced reactivation of bullous pemphigoid
    Kaul, Subuhi
    Wang, Allison
    Grushchak, Solomiya
    Albrecht, Joerg
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2021, 60 (06) : 757 - 758
  • [5] Pembrolizumab-Induced Bullous Pemphigoid Treated With Rituximab
    Sharma, Pritha
    Barnes, Martin
    Nabeel, Shaha
    LiPera, William
    JCO ONCOLOGY PRACTICE, 2020, 16 (11) : 764 - +
  • [6] A Rare Case of Pembrolizumab-Induced Hepatitis
    Chaudhry, Hunza
    Lin, Joanne
    Sohal, Aalam
    Gulati, Alakh
    Roytman, Marina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S2082 - S2082
  • [7] Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid
    Wang, Jianglin
    Hu, Xin
    Jiang, Wei
    Zhou, Wenjie
    Tang, Mengjie
    Wu, Cuifang
    Liu, Wei
    Zuo, Xiaocong
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [8] Pembrolizumab-Induced Sarcoidosis: A Case Report
    Walmsley, C. S.
    Sibert, T.
    Summers, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [9] Pembrolizumab-Induced Hypothyroidism: A Case Report
    Gaibor, Carlos
    Das, Rohan
    Reddy, Vijayakumari
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)
  • [10] Pembrolizumab-Induced Ketoacidosis: A Case Report
    Guimaraes, Francisco
    Polishchuk, Nataliya
    Martins, Claudia Almeida
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)